A new trial suggests that semaglutide, a weight-loss drug, may help treat metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition. The study showed significant improvements in liver inflammation and scarring among patients taking the drug. However, lifestyle changes also played a crucial role in the results. The drugmaker, Novo Nordisk, plans to seek regulatory approval for MASH treatment by mid-2025. Teljes cikk (Euronews.com)